News & Updates

In the treatment of adults with metabolic dysfunction–associated steatotic liver disease (MASLD), the use of docosahexaenoic acid (DHA), vitamin E, or its combination stops short of reducing liver fat or aminotransferases, according to a study.

Dual triggering with gonadotropin-releasing hormone agonist (GnRHa) and human chorionic gonadotropin (hCG) was not superior to GnRHa alone in terms of mature oocyte retrieval for elective fertility preservation, according to a study presented at ESHRE 2024.

Both galcanezumab and prednisone effectively relieve pain in people with medication overuse headache (MOH), with combination therapy using both medications yielding the greatest benefit, according to the results of a three-arm, head-to-head observational study. However, the use of prednisone is accompanied by an increased frequency of adverse events.

In the phase II OXOART2 trial presented at ESHRE 2024, the first-in-class, non-hormonal, oral agent OXO-001 increases implantation and pregnancy rates in infertile women ≤40 years undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Response-adapted radiation therapy (RT) shows promise in the treatment of indolent orbital B-cell lymphoma, conferring high local control rates while reducing radiation exposure, according to the results of a phase II nonrandomized controlled trial.

The IL-13 inhibitor cendakimab appears to be beneficial in the treatment of atopic dermatitis (AD), with the results of a phase II study showing that a dosing schedule of 720 mg once weekly helps reduce the severity of the said condition.

Argatroban appears to reduce neurological deficits in acute ischaemic stroke (AIS) patients with early neurological deterioration (END) who are undergoing thrombolytic therapy, without increasing the risk of symptomatic intracranial haemorrhage, according to the results of a meta-analysis.